Genmab — Marts 2016
-
Selvfølgelig bliver kursen ikke påvirket af dette her på nuværende tidspunkt.
-
Sådan udlægger jeg det også med hensyn til de citerede udtalelser i artiklen. Men ikke at "den er hjemme snart".

-
Det er sådan markedet tænker Legolas.
-
Det er jeg helt enig i.
-
"A Genmab acquisition by J&J becomes more and more attractive for them. They have $35 billion in cash and what happened with Pharmacyclics going to another party, won't happen again. Not that I want to sell, but if it comes to that, it will be a friendly take-over, and I expect a 100% premium from this price level."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind